Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report
نویسندگان
چکیده
منابع مشابه
Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report
BACKGROUND Coagulopathy is a major contributing factor to bleeding related mortality even after achieving adequate surgical control of the haemorrhage in trauma and surgical patients. CASE PRESENTATION A 65 years old Greek man was admitted in our ICU with critical haemorrhage following renal biopsy. Despite surgical exploration the patient continued to bleed resulting in a vicious cycle of tr...
متن کاملIntrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories
BACKGROUND Diffuse alveolar haemorrhage (DAH) is a serious pulmonary complication characterised by a high mortality rate and the absence of specific treatment. The intrapulmonary administration of activated recombinant factor VII (rFVIIa) in DAH was recently published in six patients by Heslet et al with an efficient hemostatic effect. We describe two cases of DAH treated with intrapulmonary rF...
متن کاملUse of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
BACKGROUND Complex cardiovascular surgery often results in postoperative hemorrhage. Excessive blood product use may cause systemic thrombosis, end-organ dysfunction, and edema preventing chest closure. Recombinant activated factor VII (rFVIIa) concentrate may decrease hemorrhage where other treatment measures failed. We reviewed our experience with rFVIIa after complex cardiovascular surgery. ...
متن کاملUse of recombinant activated factor VII in trauma
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conduct...
متن کاملOff-Label Use of Recombinant Activated Factor VII (NovoSeven®)
NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cases Journal
سال: 2008
ISSN: 1757-1626
DOI: 10.1186/1757-1626-1-361